PROSTALUND NORGE NUF

Closed at December 19th, 2024

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

CEO: JW
Johan Wennerholm1968
Operation time: 3 years; - Sep 17, 2021 to Dec 19, 2024
Type: Norwegian division of foreign business enterprise
VAT registered: No
Number of employees: 0

Last update: Aug 29, 2024

Management

Management / administration

Name	Role	Shares
JW Johan Wennerholm 1968	Managing Director/CEO	-

Board

Name	Role	Shares
P PROSTALUND AB	Information about the Company in the Home Country	-

Last update: Apr 13, 2023

Ownership

No available data

Financials

in NOK

Summary

Year	2023	2022
Total operating income	0	0
Annual Total Result	0	0
Total assets	0	0
Total liabilities	0	0
Total equity	0	0

P&L

Year	2023	2022
Total operating income	0	0
Total operating costs	0	0
Operating result	0	0
Financial income/costs	0	0
Profit before tax	0	0
Total tax & extraordinary income/cost	0	0
Annual Total Result	0	0

Balance overview

Year	2023	2022
Total fixed assets	0	0
Total current assets	0	0
Total assets	0	0
Short term debt	0	0
Long term debt	0	0
Total liabilities	0	0
Contributed capital	0	0
Retained earnings	0	0
Total equity	0	0
Total equity and liabilities	0	0

PROSTALUND NORGE NUF927 594 560